Five-year follow-up using a prostate stent as fiducial in image-guided radiotherapy of prostate cancer

References

• Zhang M, Moiseenko V, Liu M, Craig T. Internal fiducial markers can assist dose escalation in treatment of prostate cancer: Result of organ motion simulations. Phys Med Biol 2006;51:269–85.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012;84:125–9.
   PubMed Web of Science ®Google Scholar
• Kok D, Gill S, Bressel M, Byrne K, Kron T, Fox C, et al. Late toxicity and biochemical control in 554 prostate cancer patients treated with and without dose escalated image guided radiotherapy. Radiother Oncol 2013;107:140–6.
   PubMed Web of Science ®Google Scholar
• Sveistrup J, af Rosenschold PM, Deasy JO, Oh JH, Pommer T, Petersen PM, et al. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol 2014;9:44.
   PubMed Web of Science ®Google Scholar
• Engels B, Soete G, Verellen D, Storme G. Conformal arc radiotherapy for prostate cancer: Increased biochemical failure in patients with distended rectum on the planning computed tomogram despite image guidance by implanted markers. Int J Radiat Oncol Biol Phys 2009;74:388–91.
   PubMed Web of Science ®Google Scholar
• Heemsbergen WD, Al-Mamgani A, Witte MG, van Herk M, Lebesque JV. Radiotherapy with rectangular fields is associated with fewer clinical failures than conformal fields in the high-risk prostate cancer subgroup: Results from a randomized trial. Radiother Oncol 2013;107:134–9.
   PubMed Web of Science ®Google Scholar
• Moman MR, van der Heide UA, Kotte AN, van Moorselaar RJ, Bol GH, Franken SP, et al. Long-term experience with transrectal and transperineal implantations of fiducial gold markers in the prostate for position verification in external beam radiotherapy; feasibility, toxicity and quality of life. Radiother Oncol 2010;96:38–42.
   PubMed Web of Science ®Google Scholar
• Carl J, Nielsen J, Holmberg M, Hojkjaer LE, Fabrin K, Fisker RV. A new fiducial marker for image-guided radiotherapy of prostate cancer: Clinical experience. Acta Oncol 2008;47:1358–66.
   PubMed Web of Science ®Google Scholar
• Carl J, Lund B, Larsen EH, Nielsen J. Feasibility study using a Ni-Ti stent and electronic portal imaging to localize the prostate during radiotherapy 1. Radiother Oncol 2006; 78:199–206.
   PubMed Web of Science ®Google Scholar
• Korsager AS, Carl J, Ostergaard LR. MR-CT registration using a Ni-Ti prostate stent in image-guided radiotherapy of prostate cancer. Med Phys 2013;40:061907.
   Google Scholar
• Carl J, Nielsen J, Holmberg M, Larsen EH, Fabrin K, Fisker RV. Clinical results from first use of prostate stent as fiducial for radiotherapy of prostate cancer. Acta Oncol 2011;50:547–54.
   PubMed Web of Science ®Google Scholar
• Sander L, Langkilde NC, Holmberg M, Carl J. MRI target delineation may reduce long-term toxicity after prostate radiotherapy. Acta Oncol 2014;53:809–14.
   PubMed Web of Science ®Google Scholar
• Michalski J, Winter K, Roach M, Markoe A, Sandler HM, Ryu J, et al. Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys 2012;83:e363–70.
   Google Scholar
• Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. Br J Urol Int 2012;109(Suppl 1):22–9.
   Google Scholar
• Martin JM, Bayley A, Bristow R, Chung P, Gospodarowicz M, Menard C, et al. Image guided dose escalated prostate radiotherapy: Still room to improve. Radiat Oncol 2009;4:50.
   PubMed Web of Science ®Google Scholar
• Ohri N, Dicker AP, Showalter TN. Late toxicity rates following definitive radiotherapy for prostate cancer. Can J Urol 2012;19:6373–80.
   PubMed Web of Science ®Google Scholar
• Crehange G, Mirjolet C, Gauthier M, Martin E, Truc G, Peignaux-Casasnovas K, et al. Clinical impact of margin reduction on late toxicity and short-term biochemical control for patients treated with daily on-line image guided IMRT for prostate cancer. Radiother Oncol 2012;103:244–6.
   PubMed Web of Science ®Google Scholar
• Syndikus I, Morgan RC, Sydes MR, Graham JD, Dearnaley DP. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: Results from the UK Medical Research Council RT01 Trial (Isrctn47772397). Int J Radiat Oncol Biol Phys 2010;77:773–83.
   PubMed Web of Science ®Google Scholar
• Fonteyne V, Villeirs G, Lumen N, De Meerleer G. Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer. Radiother Oncol 2009;92:42–7.
   PubMed Web of Science ®Google Scholar
• Malik R, Jani AB, Liauw SL. External beam radiotherapy for prostate cancer: Urinary outcomes for men with high International Prostate Symptom Scores (IPSS). Int J Radiat Oncol Biol Phys 2011;80:1080–6.
   PubMed Web of Science ®Google Scholar